Company: Canopy Growth
Job title: Associate Director of Cannabinoid Research
Hunter Land, MS is the Associate Director of Cannabinoid Research at Canopy Growth Corporation, the world’s largest cannabis producer. Prior to joining Canopy, Land was employed by GW pharmaceuticals, holding roles in the R&D and Medical Department. Academically trained in Biochemistry and Nutrition, Land started university research in 2005 and transitioned to clinical research in 2006 where he worked for multiple research organizations in clinical development. He was hired by GW Pharmaceuticals in 2013 as the first US based clinical development employee and established the US research team. Mr. Land designed and authored multiple protocols in refractory epilepsy (Dravet Syndrome and LGS), Multiple Sclerosis, pain and led the clinical development of Epidiolex (FDA approved CBD). Additionally, Land led the investigator-initiated research committee, established US pre-clinical university collaborations and initiated global discovery pipeline work on novel cannabinoid formulations. He continues to closely collaborate with world leading cannabinoid, neurology and epilepsy experts while focusing on applications of cannabinoid formulations and their utility across a variety of conditions. He is frequently featured as a keynote speaker at various cannabinoid and scientific conferences, provides scientific training at university grand rounds and was featured in Forbes magazine as a cannabinoid subject matter expert. Land is a co-founder of the Cannabinoid Education Working Group and a contributing member of the International Cannabinoid Research Society, American Epilepsy Society and the American Academy of Neurology.
Live Q&A 3:00 pm - 3:15 am
day: Day Two
Assessing the Potential Clinical Value of the Next Hopefuls in Cannabinoid Pharmaceutical APIs: CBG, CBN and THCA 2:00 pm
Preclinical evidence for the use of novel minor cannabinoids Minor cannabinoid safety and toxicity Where is the clinical evidence?Read more
day: Day Two